Login / Signup

Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.

Ronald ChowLeonard ChiuJørn HerrstedtMatti AaproMichael LockCarlo DeAngelisRudolph M Navari
Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)
Olanzapine-containing regimens are both cheaper and more effective in the prophylaxis of CINV in HEC patients, compared with non-olanzapine-containing regimens. Future CINV trial resources should be allocated to understand newer antiemetics and compare them to olanzapine-containing regimens as the control arm. Further analysis should use nationally representative data to examine medication costs by payer type.
Keyphrases